報價延遲最少15分鐘:2025/07/21 11:03 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.7217 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.75/-3.64
|
|
企業價值
279.77M
|
| 資產負債 |
|
每股賬面淨值
0.11
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/21 11:03 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE. |
